SWM
VNDA icon

SHP Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

SHP Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$441 – 1910
2025
Q4 		$441 Buy
+50
New +$275 ﹤0.01% 1385

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SHP Wealth Management's VNDA Position: Q1 2026 in Review

SHP Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 50 shares — an estimated $441 sold.

SHP Wealth Management first reported a position in VNDA in Q4 2025 and held it in 1 quarter. The position peaked at $441 in Q4 2025. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • SHP Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SHP Wealth Management sold 50 Vanda Pharmaceuticals shares in Q1 2026, an estimated $441.
  • SHP Wealth Management first reported a position in Vanda Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SHP Wealth Management's Vanda Pharmaceuticals position peaked at $441 in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.